🔗 Visit the ClinicalTrials.gov page for NCT01922076
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | The Efficacy of the Wee1 Inhibitor MK-1775 Combined with Temozolomide Is Limited by Heterogeneous Distribution across the Blood-Brain Barrier in Glioblastoma. | Clin Cancer Res | 2015 | 0.95 |
| 2 | Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. | Mol Cancer | 2014 | 0.91 |
| 3 | Molecular Pathways: Overcoming Radiation Resistance by Targeting DNA Damage Response Pathways. | Clin Cancer Res | 2015 | 0.90 |
| 4 | Identification of clinically achievable combination therapies in childhood rhabdomyosarcoma. | Cancer Chemother Pharmacol | 2016 | 0.75 |
| 5 | Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities. | J Pediatr Hematol Oncol | 2016 | 0.75 |